Dangerous Research Regs Released

The US government releases its policy on so-called dual-use research involving dangerous pathogens that could be used for biological terrorist attacks.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, CSIROThe 2012 creation of H5N1 bird flu strains that can be transmitted between ferrets spurred a debate among the scientific community about how such research, which could have deadly applications in the hands of bioterrorists, should be regulated. In February 2013, the US government issued a draft policy on such dual-use research, which collected 38 comments from institutions and researchers over the months that followed, Nature News blog reported. Yesterday (September 24), the final policy debuted; it contains guidelines for researchers studying any of 15 dangerous pathogens, including the avian influenza virus that brought these issues to the fore and the Ebola virus that continues to wreak havoc in West Africa.

The rules are intended to “preserve the benefits of life-science research while minimizing the risk of misuse,” National Institutes of Health (NIH) Director Francis Collins told The New York Times (NYT).

The policy, which will take effect next year, requires federally funded scientists working with these pathogens to alert their institutions to any potential of misuse of their research and states that it is the institutions responsibility to then decide if the work qualifies as dual-use research of concern (DURC). The report also notes that funding for such research will be highly scrutinized. Interestingly, the policy leaves out specific mention of gain-of-function research, such as that which rendered the H5N1 virus transmissible between mammals. Such experiments “would be outside the scope of the current framework,” ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies